Compare Salesforce Inc (CRM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Merck & Co., Inc. — how do they compare? Salesforce Inc trades at $168.47 (market cap $137.23B), while Merck & Co., Inc. trades at $123.94 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 2.2× Salesforce Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| CRM | MRK | |
|---|---|---|
Market Cap | $137.23B | $298.31B |
Sector | Technology | Health |
52-Week High | $270.25 | $129.52 |
52-Week Low | $150.12 | $77.60 |
Enterprise Value | $167.28B | $341.72B |
Dividend Yield | 1.05% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% today, but remains down significantly year-to-date amid a broader software sell-off. The company demonstrates strong fundamentals with revenue growth to $37.90B in 2025 and a net income margin of 18.73%. Recent quarters show consistent earnings beats, and analyst consensus remains strongly bullish with a $235.90 price target. Technical indicators are mixed, with the stock near key support at $167.
The outlook is positive for long-term investors given robust profitability, AI-driven growth initiatives, and a discounted valuation. Key risks include intense competition in the SaaS sector and macroeconomic sensitivity. The current price presents a potential entry point relative to analyst targets, but volatility may persist in the near term.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
